HK1175456A1 - 抗利什曼原蟲化合物以及抗利什曼原蟲藥 - Google Patents

抗利什曼原蟲化合物以及抗利什曼原蟲藥

Info

Publication number
HK1175456A1
HK1175456A1 HK13102786.9A HK13102786A HK1175456A1 HK 1175456 A1 HK1175456 A1 HK 1175456A1 HK 13102786 A HK13102786 A HK 13102786A HK 1175456 A1 HK1175456 A1 HK 1175456A1
Authority
HK
Hong Kong
Prior art keywords
leishmania
drug
compound
leishmania compound
leishmania drug
Prior art date
Application number
HK13102786.9A
Other languages
English (en)
Inventor
Kimura Junji
Horie Shohei
Marushima Harumi
Matsumoto Yoshitsugu
Sanjoba Chizu
Osada Yasutaka
Original Assignee
學校法人青山學院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45974960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1175456(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 學校法人青山學院 filed Critical 學校法人青山學院
Publication of HK1175456A1 publication Critical patent/HK1175456A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/38—Quinones containing —CHO or non—quinoid keto groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/02—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains containing only carbon and hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C07C403/16—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms not being part of —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/02—Quinones with monocyclic quinoid structure
    • C07C50/06—Quinones with monocyclic quinoid structure with unsaturation outside the quinoid structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/38—Unsaturated compounds containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C66/00—Quinone carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
HK13102786.9A 2010-10-19 2013-03-06 抗利什曼原蟲化合物以及抗利什曼原蟲藥 HK1175456A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010234923 2010-10-19
PCT/JP2011/073482 WO2012053408A1 (ja) 2010-10-19 2011-10-13 抗リーシュマニア化合物及び抗リーシュマニア薬

Publications (1)

Publication Number Publication Date
HK1175456A1 true HK1175456A1 (zh) 2013-07-05

Family

ID=45974960

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13102787.8A HK1175457A1 (en) 2010-10-19 2013-03-06 Anti-leishmania compound and anti-leishmania drug
HK13102786.9A HK1175456A1 (zh) 2010-10-19 2013-03-06 抗利什曼原蟲化合物以及抗利什曼原蟲藥

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13102787.8A HK1175457A1 (en) 2010-10-19 2013-03-06 Anti-leishmania compound and anti-leishmania drug

Country Status (7)

Country Link
US (1) US8809555B2 (zh)
EP (4) EP2557076B1 (zh)
JP (5) JP4987173B2 (zh)
KR (2) KR101114629B1 (zh)
CN (2) CN102753521B (zh)
HK (2) HK1175457A1 (zh)
WO (2) WO2012053232A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675684B2 (en) 2013-03-28 2017-06-13 The United States Of America As Represented By The Secretary Of The Army Gene optimized hantaan virus M segment DNA vaccine for hemorrhagic fever with renal syndrome
JP6630343B2 (ja) * 2015-03-19 2020-01-15 第一三共株式会社 抗酸化剤を含有する固形製剤
US12083226B2 (en) 2018-07-30 2024-09-10 Daiichi Sankyo Company, Limited Stabilizer-containing solid drug formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006439A1 (en) * 1992-09-22 1994-03-31 Department Of The Army, United States Government Antileishmanial composition for topical application
JP3418724B2 (ja) * 2000-02-10 2003-06-23 国立医薬品食品衛生研究所長 セスキテルペノイド化合物及びそれを含む医薬
JP2004331545A (ja) 2003-05-06 2004-11-25 Japan Science & Technology Agency 抗リーシュマニア剤
US20080254136A1 (en) 2004-07-30 2008-10-16 Japan Health Sciences Foundation Antiprotozoal Agent
JP2006321728A (ja) 2005-05-17 2006-11-30 Osaka Bioscience Institute 新規な抗リーシュマニア医薬組成物
JP4762381B1 (ja) * 2010-10-19 2011-08-31 学校法人青山学院 抗リーシュマニア化合物及び抗リーシュマニア薬

Also Published As

Publication number Publication date
EP2557076B1 (en) 2013-10-09
JP2012131805A (ja) 2012-07-12
WO2012053232A1 (ja) 2012-04-26
JP5044050B2 (ja) 2012-10-10
EP2520562B1 (en) 2014-08-13
KR101114629B1 (ko) 2012-03-13
JP5044052B2 (ja) 2012-10-10
EP2557076A4 (en) 2013-04-24
EP2668950A1 (en) 2013-12-04
JP2012131804A (ja) 2012-07-12
KR101232552B1 (ko) 2013-02-12
US20130245288A1 (en) 2013-09-19
EP2557076A8 (en) 2013-04-10
JP5044051B2 (ja) 2012-10-10
JPWO2012053408A1 (ja) 2014-02-24
EP2668946A1 (en) 2013-12-04
EP2668946B1 (en) 2014-08-13
CN102753521A (zh) 2012-10-24
HK1175457A1 (en) 2013-07-05
EP2520562A4 (en) 2013-07-03
CN102811992B (zh) 2015-06-17
EP2668950B1 (en) 2014-08-13
WO2012053408A1 (ja) 2012-04-26
EP2557076A1 (en) 2013-02-13
JP2012131807A (ja) 2012-07-12
JP2012131806A (ja) 2012-07-12
JP5044053B2 (ja) 2012-10-10
KR20120099298A (ko) 2012-09-07
EP2520562A1 (en) 2012-11-07
US8809555B2 (en) 2014-08-19
JP4987173B2 (ja) 2012-07-25
CN102753521B (zh) 2013-07-10
CN102811992A (zh) 2012-12-05

Similar Documents

Publication Publication Date Title
IL253870B (en) Certain amino-pyrimidines and pharmaceutical preparations containing them
IL226245A0 (en) History
IL222176B (en) Radioprotector compounds and methods
IL220939A0 (en) Compounds and methods
EP2523664A4 (en) COMPOUNDS AND METHODS
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
IL220812A0 (en) Compounds and methods
AP2013006947A0 (en) Compounds and their use
EP2523560A4 (en) CONNECTIONS AND METHODS
EP2575453A4 (en) OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE
EP2636666A4 (en) TRANS-2 DECENTRIC ACID DERIVATIVES AND MEDICAMENTS CONTAINING THEREOF
HRP20141173T1 (hr) Medikament koji sadrži miramistin
IL223707A0 (en) N-hydroxyformamide derivative and medicament containing same
EP2564852A4 (en) MEDICAMENT TREATING CEREBRAL TUMORS
EP2615094A4 (en) SESTERTERPEN COMPOUNDS AND THEIR USE
HK1175456A1 (zh) 抗利什曼原蟲化合物以及抗利什曼原蟲藥
EP2638160A4 (en) NUCLIONS AND RIBOCAPSIDES
GB201002451D0 (en) Pharmaceutical comopitions and devices
GB201014319D0 (en) Compounds and uses thereof
GB201001317D0 (en) Medicament
EP2567956A4 (en) NEW PRENYLAR CONNECTION AND USE THEREOF
GB201005712D0 (en) Medicaments and their manufacture
GB201001383D0 (en) New compounds and medical uses
GB201001364D0 (en) New compounds and medical uses
GB201001376D0 (en) New compounds and medical uses

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20231017